Form 4: Cyclerion Therapeutics Executive Regina Graul Acquires Stock Options

Regina Graul, President and CEO of Cyclerion Therapeutics, was granted options to purchase 55,849 shares of the company's common stock.

Summary

• Regina Margaret Graul, President and CEO of Cyclerion Therapeutics, Inc., was granted stock options on August 5, 2024.
• The options allow her to purchase up to 55,849 shares of Cyclerion's common stock at an exercise price of $3.30 per share.
• The options were granted pursuant to the 2019 Equity Incentive Plan.
• The options vest ratably in monthly installments over a 48-month period, commencing August 31, 2024, and ending July 31, 2028, contingent upon continued employment.
• The options expire on August 5, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. It's a neutral-positive event.

Positives

• The grant of stock options aligns the executive's interests with those of the shareholders, incentivizing her to improve the company's performance.
• The vesting schedule encourages long-term commitment from the executive.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the options.

Management Comments

• Regina M. Graul signed the document as President and Chief Executive Officer.

Industry Context

Stock option grants are a common practice in the biotechnology industry to attract and retain key executives and align their interests with those of shareholders. The size and vesting schedule of the grant are typical for executive compensation packages in similar companies.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation in the biotech industry.
• Companies like BioMarin Pharmaceutical and Vertex Pharmaceuticals also utilize stock options as part of their executive compensation packages.
• The vesting schedule of 48 months is a common practice to ensure long-term commitment.

Stakeholder Impact

• Shareholders may view the option grant positively as it incentivizes the CEO to increase shareholder value.
• Employees may see it as a sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, Cyclerion Therapeutics, Regina Graul, executive compensation, Form 4, CYCN, equity incentive plan